Literature DB >> 17967209

Parthenogenetic activation of bovine oocytes using single and combined strontium, ionomycin and 6-dimethylaminopurine treatments.

S C Méo1, W Yamazaki, C R Ferreira, F Perecin, N Z Saraiva, C L V Leal, J M Garcia.   

Abstract

In vitro-matured (IVM) bovine oocytes were activated with single and combined treatments of strontium (S), ionomycin (I) and 6-DMAP (D). Using oocytes IVM for 26 h, we observed that activation altered cell cycle kinetics (faster progression, MIII arrest, or direct transition from MII to pronuclear stage) when compared to in vitro fertilization. The effect of oocyte age on early parthenogenesis was assessed in oocytes IVM for 22, 26 and 30 h. Better results in pronuclear development were obtained in treatments ISD (81.7%) at 22 h; D (66.7%), IS (63.3%), ID (73.3%) and ISD (76.7%) at 26 h; and D (86.7%), IS (85.0%) and ID (78.3%) at 30 h. Higher cleavage occurred on ISD (80.0%) at 22 h; ID (83.3%) and ISD (91.7%) at 26 h; and I (86.7%), IS (90.0%), ID (85.0%) and ISD (95.0%) at 30 h. More blastocysts were achieved in ID (25.0%) and ISD (18.3%) at 22 h; and in ID at 26 h (45.0%) and 30 h (50.0%). We also observed that IS allowed higher haploid (77.4%) embryonic development, whilst ID was better for diploid (89.1%) development. It was concluded that association of S and D without I was not effective for blastocyst development; treatments using S were less influenced by oocyte age, but when S was associated with D there was a detrimental effect on aged oocytes; treatment ISD promoted higher activation and cleavage rates in young oocytes and ID protocol was the best for producing blastocysts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967209     DOI: 10.1017/S0967199407004285

Source DB:  PubMed          Journal:  Zygote        ISSN: 0967-1994            Impact factor:   1.442


  7 in total

1.  Analysis of clinical outcomes with respect to spermatozoan origin after artificial oocyte activation with a calcium ionophore.

Authors:  Hye Jin Yoon; In Hee Bae; Hyoung Jun Kim; Jung Mi Jang; Yong Su Hur; Hae Kwon Kim; San Hyun Yoon; Won Don Lee; Jin Ho Lim
Journal:  J Assist Reprod Genet       Date:  2013-10-10       Impact factor: 3.412

2.  The use of parthenotegenetic and IVF bovine blastocysts as a model for the creation of human embryonic stem cells under defined conditions.

Authors:  R R Ruggeri; Y Watanabe; F Meirelles; F F Bressan; N Frantz; A Bos-Mikich
Journal:  J Assist Reprod Genet       Date:  2012-09-29       Impact factor: 3.412

3.  Analysis of cat oocyte activation methods for the generation of feline disease models by nuclear transfer.

Authors:  Chunmin Wang; William F Swanson; Jason R Herrick; Kiho Lee; Zoltan Machaty
Journal:  Reprod Biol Endocrinol       Date:  2009-12-11       Impact factor: 5.211

4.  Parthenogenetic bovine embryos secrete type I interferon capable of stimulating ISG15 in luteal cell culture.

Authors:  Alessandra Bridi; Kalyne Bertolin; Vitor B Rissi; Lady K S Mujica; Werner G Glanzner; Mariana P de Macedo; Fabio V Comim; Paulo B D Gonçalves; Alfredo Q Antoniazzi
Journal:  Anim Reprod       Date:  2018-12-05       Impact factor: 1.807

5.  Effect of calcium ionophore on unfertilized oocytes after ICSI cycles.

Authors:  Maryam Eftekhar; Farnaz Mohammadian; Fariba Yousefnejad; Parisa Khani; Abbas Aflatoonian
Journal:  Iran J Reprod Med       Date:  2012-03

6.  Effects of assisted oocyte activation with calcium- ionophore and strontium chloride on in vitro ICSI outcomes.

Authors:  Marziyeh Norozi-Hafshejani; Marziyeh Tavalaee; Leila Azadi; Mehrnoosh Bahadorani; Mohammad Hossein Nasr-Esfahani
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

7.  Effect of Ethanol on Parthenogenetic Activation and α-Tocopherol Supplementation during In Vitro Maturation on Developmental Competence of Summer-Collected Bovine Oocytes.

Authors:  Francisco Báez; Belén Gómez; Victoria de Brun; Nélida Rodríguez-Osorio; Carolina Viñoles
Journal:  Curr Issues Mol Biol       Date:  2021-12-16       Impact factor: 2.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.